Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Studies Done by Stephen Olson at University of Minnesota 2001 Through 2013

Studies Done by Stephen Olson at University of Minnesota 2001 Through 2013

Ratings: (0)|Views: 39 |Likes:
Published by MarkingsonCase
Studies conducted by Stephen Olson at the University of Minnesota from 2001 through 2013, according to university records manager Susan McKinney.
Studies conducted by Stephen Olson at the University of Minnesota from 2001 through 2013, according to university records manager Susan McKinney.

More info:

Categories:Types, Business/Law
Published by: MarkingsonCase on Jan 09, 2014
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

03/04/2014

pdf

text

original

 
 
49 Olson, Stephen 0102M82681 A Randomized, Open-Label, Rater-Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine (Risperidone Rescue Study) Janssen Pharmaceutica Protocol RIS-USA-250 3/20/2001 5/22/2002 50 Olson, Stephen 0102M82701 A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation Quetiapine Fumarate (Seroquel TM) and Placebo in the Treatment of Patients with Schizophrenia AstraZeneca Protocol 5077IL/0041 4/9/2001 12/27/2002 51 Olson, Stephen 0111M12742 Comparative Effectiveness of Antipsychotic Medications in Patients with Schizophrenia-Clinical Antipsychotic Trials of Intervention Effectiveness - The CATIE Study 2/11/2002 7/22/2005 52 Olson, Stephen 0202M17441 Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison - The Cafe Study 4/22/2002 8/8/2005 53 Olson, Stephen 0206M26802 Diagnostic Assessment Core (DAC) for Studies in Schizophrenia and Related Disorders 7/31/2002 7/11/2008
 
 
54 Olson, Stephen 0309M52650 Protocol HGU-MC-HGLM 12/18/2003 6/28/2006 55 Olson, Stephen 0309M52651 A Randomized, Double-Blind, Placebo-Controlled and Risperdone- Referenced, Parallel-Group Efficacy and Safety of Two Fixed Doses of Bifeprunox in the Treatment of Schizophrenia (Protocol S1543001) 3/18/2004 8/23/2005 56 Olson, Stephen 0309M52653 An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizophrenia, Protocol S1543002 (Extension of Protocol S1543001) 3/18/2004 8/22/2008 57 Olson, Stephen 0310M53142 A Multicenter, Open-label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL) and Risperdone (RISPERDAL) in the Long-term Treatment of Patients with Schizophrenia or Schizoaffective Disorder Protocol 5077IL/0089 2/25/2004 11/13/2008 58 Olson, Stephen 0407M61923 An Double-Blind Randomized Study Comparing Intramuscular Olanzapine Depot with Placebo in the Treatment of Patients with Schizophrenia, Protocol F1D-MC-HGJZ(b) 9/21/2004 7/11/2005 59 Olson, Stephen 0407M61924 An Open-Label Study of Intramuscular Olanzapine Depot in Patients with Schizophrenia or Schizoaffective Disorder, Protocol F1D-MC-HGKB(b) 9/21/2004 7/11/2005 60 Olson, Stephen 0509M73986 A Randomized, Placebo-Controlled, Double-Blind Trial of Asenapine in the Prevention of Relapse after Long-Term Treatment of Schizophrenia 1/5/2006 11/20/2008 61 Olson, Stephen 0602M81590 A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Subjects who Completed Protocol A7501013 (Protocol A7501014) 7/31/2006 1/27/2008 62 Olson, Stephen 0602M81591 A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia (Protocol A7501013) 6/29/2006 1/27/2008 63 Olson, Stephen 0603M83470 A Multicenter, Double-Blind, Randomized, Parallel Group, Active-Controlled Tolerability and Safety Study of MK-3756(SM-13496/Lurasidone) in Clinically Stable Schizophrenia Outpatients 7/14/2006 1/4/2007
 
 
64 Olson, Stephen 0603M84169 Effectiveness of Switching from Injectable Conventional Antipsychotic Medications to Injectable Risperidone(Switch or Stay) 7/19/2006 1/15/2010 65 Olson, Stephen 0606M87346 Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy (Stay or Switch Study) 7/19/2006 1/15/2010 66 Olson, Stephen 0606M88386 A Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia (F1D-MC-HGLB(a)) 9/15/2006 4/23/2007 67 Olson, Stephen 0607M90126 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy (CN 138397) 9/21/2006 2/5/2008 68 Olson, Stephen 0608M90546 A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects with Psychosis (Protocol A 7501021) 3/6/2007 8/1/2008 69 Olson, Stephen 0609M93066 Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to Aripiprazole versus Continued Treatment with Olanzapine, Quetiapine, or Risperidone Comparison of Antipsychotics for Metabolic Problems (the CAMP study) 11/28/2006 7/14/2011 70 Olson, Stephen 0610M95446 A Multi-Center, Open-Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching from Existing Atypical Antipsychotics to Bifeprunox in Subjects with Schizophrenia or Schizoaffective Disorder. Protocol S1543020 1/23/2007 5/8/2008 71 Olson, Stephen 0701M00343 A 24-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of AVE 1625 5, 10, and 30 mg and Placebo on Top of an Established Treatment Regimen of either Olanzapine, Risperidone or Quetiapine Monotherapy in the Treatment of Cognitive Impairment in Schizophrenia 3/12/2007 12/4/2009 72 Olson, Stephen 0703M04621 Validation of the Reasons for Antipsychotic Discontinuation/Continuation Questionnaire (RAD-Q) and Interview (RAD-I) 5/3/2007 3/11/2009

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->